More about

Thyroid Eye Disease

News
July 31, 2020
3 min read
Save

Top-line data demonstrate efficacy, safety of teprotumumab for thyroid eye disease

Top-line data demonstrate efficacy, safety of teprotumumab for thyroid eye disease

Most adults with thyroid eye disease who experienced meaningful improvement in proptosis after 21 weeks of teprotumumab treatment maintained proptosis response at week 72 without additional treatment, according to top-line data.

News
April 02, 2020
3 min read
Save

Smokers, women experience proptosis reduction with teprotumumab in thyroid eye disease

Smokers, women experience proptosis reduction with teprotumumab in thyroid eye disease

High-risk adults with active thyroid eye disease, such as smokers, women and older adults, experienced a reduction in outward bulging of the eye at 24 weeks that was similar to adults at lower risk for the disease, according to findings accepted for presentation at the Endocrine Society Annual Meeting.

News
March 31, 2020
1 min read
Save

Immunovant’s thyroid eye disease treatment shows positive phase 2a results

IMVT-1401, a thyroid eye disease treatment candidate, showed a 65% improvement in IgG levels in a phase 2a proof-of-concept study, Immunovant announced in a press release.

News
January 29, 2020
1 min read
Save

Top stories in endocrinology: Blood test estimates final menstrual period, FDA OKs novel thyroid eye disease treatment

Top stories in endocrinology: Blood test estimates final menstrual period, FDA OKs novel thyroid eye disease treatment

Researchers said a blood test can show when a woman may experience her last menstrual period. This was the top story in endocrinology last week.

News
January 23, 2020
2 min read
Save

Teprotumumab improves proptosis, quality of life for adults with thyroid eye disease

Teprotumumab improves proptosis, quality of life for adults with thyroid eye disease

Adults with thyroid eye disease assigned the human monoclonal antibody teprotumumab were significantly more likely to experience a meaningful improvement in proptosis after 21 weeks of treatment compared with those who received placebo, according to findings from a randomized controlled trial published in The New England Journal of Medicine.

News
January 21, 2020
3 min read
Save

FDA approves teprotumumab for thyroid eye disease

FDA approves teprotumumab for thyroid eye disease

The FDA on Tuesday approved the human monoclonal antibody teprotumumab for the treatment of adults with thyroid eye disease, marking the first drug approved for the condition, according to an agency press release.

News
January 18, 2020
2 min read
Save

Teprotumumab significantly improves proptosis in thyroid eye disease

Teprotumumab significantly improves proptosis in thyroid eye disease

KOLOA, Hawaii — Patients with thyroid eye disease treated with teprotumumab demonstrated a significant reduction in proptosis compared with those treated with placebo, according to phase 3 results from the OPTIC trial.

News
January 18, 2020
2 min read
Save

AACE launches ‘Up to Here’ thyroid awareness campaign

AACE launches ‘Up to Here’ thyroid awareness campaign

The American Association of Clinical Endocrinologists this week launched the Up To Here campaign to raise awareness of thyroid diseases and to help U.S. residents recognize symptoms, risk factors and the need to seek treatment, according to an association press release.

News
December 31, 2019
2 min read
Save

Stem cell therapy, FDA approvals lead 2019 ophthalmology news

Ophthalmology news in 2019 included FDA approvals and breakthrough study results.

News
December 28, 2019
2 min read
Save

Top thyroid news 2019: treating refractory cancer, thyroid eye disease and more

Top thyroid news 2019: treating refractory cancer, thyroid eye disease and more

In 2019, Healio readers were interested in thyroidectomy for Hashimoto’s disease, environmental effects on thyroid function, the limits of thyroid testing, a drug under FDA consideration for thyroid eye disease, subclinical hypothyroidism guidelines, and more.

View more